These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 28985758)

  • 1. Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells.
    Megiorni F; Gravina GL; Camero S; Ceccarelli S; Del Fattore A; Desiderio V; Papaccio F; McDowell HP; Shukla R; Pizzuti A; Beirinckx F; Pujuguet P; Saniere L; der Aar EV; Maggio R; De Felice F; Marchese C; Dominici C; Tombolini V; Festuccia C; Marampon F
    J Hematol Oncol; 2017 Oct; 10(1):161. PubMed ID: 28985758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Key role of MEK/ERK pathway in sustaining tumorigenicity and in vitro radioresistance of embryonal rhabdomyosarcoma stem-like cell population.
    Ciccarelli C; Vulcano F; Milazzo L; Gravina GL; Marampon F; Macioce G; Giampaolo A; Tombolini V; Di Paolo V; Hassan HJ; Zani BM
    Mol Cancer; 2016 Feb; 15():16. PubMed ID: 26897742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNMT3B in vitro knocking-down is able to reverse embryonal rhabdomyosarcoma cell phenotype through inhibition of proliferation and induction of myogenic differentiation.
    Megiorni F; Camero S; Ceccarelli S; McDowell HP; Mannarino O; Marampon F; Pizer B; Shukla R; Pizzuti A; Marchese C; Clerico A; Dominici C
    Oncotarget; 2016 Nov; 7(48):79342-79356. PubMed ID: 27764816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumorigenic Effects of Inhibiting Ephrin Receptor Kinase Signaling by GLPG1790 against Colorectal Cancer Cell Lines
    Colapietro A; Gravina GL; Petragnano F; Fasciani I; Scicchitano BM; Beirinckx F; Pujuguet P; Saniere L; Van der Aar E; Musio D; De Felice F; Mattei V; Martellucci S; Maggio R; Tombolini V; Festuccia C; Marampon F
    J Oncol; 2020; 2020():9342732. PubMed ID: 32184826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Small Molecule Ephrin Receptor Inhibitor, GLPG1790, Reduces Renewal Capabilities of Cancer Stem Cells, Showing Anti-Tumour Efficacy on Preclinical Glioblastoma Models.
    Gravina GL; Mancini A; Colapietro A; Delle Monache S; Sferra R; Vitale F; Cristiano L; Martellucci S; Marampon F; Mattei V; Beirinckx F; Pujuguet P; Saniere L; Lorenzon G; van der Aar E; Festuccia C
    Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30871240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical rationale for entinostat in embryonal rhabdomyosarcoma.
    Bharathy N; Berlow NE; Wang E; Abraham J; Settelmeyer TP; Hooper JE; Svalina MN; Bajwa Z; Goros MW; Hernandez BS; Wolff JE; Pal R; Davies AM; Ashok A; Bushby D; Mancini M; Noakes C; Goodwin NC; Ordentlich P; Keck J; Hawkins DS; Rudzinski ER; Mansoor A; Perkins TJ; Vakoc CR; Michalek JE; Keller C
    Skelet Muscle; 2019 May; 9(1):12. PubMed ID: 31113472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous targeting of insulin-like growth factor-1 receptor and anaplastic lymphoma kinase in embryonal and alveolar rhabdomyosarcoma: a rational choice.
    van Gaal JC; Roeffen MH; Flucke UE; van der Laak JA; van der Heijden G; de Bont ES; Suurmeijer AJ; Versleijen-Jonkers YM; van der Graaf WT
    Eur J Cancer; 2013 Nov; 49(16):3462-70. PubMed ID: 23867124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defective RAGE activity in embryonal rhabdomyosarcoma cells results in high PAX7 levels that sustain migration and invasiveness.
    Chiappalupi S; Riuzzi F; Fulle S; Donato R; Sorci G
    Carcinogenesis; 2014 Oct; 35(10):2382-92. PubMed ID: 25123133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Romidepsin (FK228) fails in counteracting the transformed phenotype of rhabdomyosarcoma cells but efficiently radiosensitizes, in vitro and in vivo, the alveolar phenotype subtype.
    Rossetti A; Petragnano F; Milazzo L; Vulcano F; Macioce G; Codenotti S; Cassandri M; Pomella S; Cicchetti F; Fasciani I; Antinozzi C; Di Luigi L; Festuccia C; De Felice F; Vergine M; Fanzani A; Rota R; Maggio R; Polimeni A; Tombolini V; Gravina GL; Marampon F
    Int J Radiat Biol; 2021; 97(7):943-957. PubMed ID: 33979259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS.
    Ciarapica R; Carcarino E; Adesso L; De Salvo M; Bracaglia G; Leoncini PP; Dall'agnese A; Verginelli F; Milano GM; Boldrini R; Inserra A; Stifani S; Screpanti I; Marquez VE; Valente S; Mai A; Puri PL; Locatelli F; Palacios D; Rota R
    BMC Cancer; 2014 Feb; 14():139. PubMed ID: 24575771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. c-Myc Sustains Transformed Phenotype and Promotes Radioresistance of Embryonal Rhabdomyosarcoma Cell Lines.
    Gravina GL; Festuccia C; Popov VM; Di Rocco A; Colapietro A; Sanità P; Monache SD; Musio D; De Felice F; Di Cesare E; Tombolini V; Marampon F
    Radiat Res; 2016 Apr; 185(4):411-22. PubMed ID: 27104757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MEK/ERK inhibitor U0126 affects in vitro and in vivo growth of embryonal rhabdomyosarcoma.
    Marampon F; Bossi G; Ciccarelli C; Di Rocco A; Sacchi A; Pestell RG; Zani BM
    Mol Cancer Ther; 2009 Mar; 8(3):543-51. PubMed ID: 19258428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A dysfunctional miR-1-TRPS1-MYOG axis drives ERMS by suppressing terminal myogenic differentiation.
    Hüttner SS; Henze H; Elster D; Koch P; Anderer U; von Eyss B; von Maltzahn J
    Mol Ther; 2023 Sep; 31(9):2612-2632. PubMed ID: 37452493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SMYD1 and G6PD modulation are critical events for miR-206-mediated differentiation of rhabdomyosarcoma.
    Coda DM; Lingua MF; Morena D; Foglizzo V; Bersani F; Ala U; Ponzetto C; Taulli R
    Cell Cycle; 2015; 14(9):1389-402. PubMed ID: 25644430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of the Notch-Hey1 axis blocks embryonal rhabdomyosarcoma tumorigenesis.
    Belyea BC; Naini S; Bentley RC; Linardic CM
    Clin Cancer Res; 2011 Dec; 17(23):7324-36. PubMed ID: 21948088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Focal adhesion kinase (FAK) phosphorylation is a key regulator of embryonal rhabdomyosarcoma (ERMS) cell viability and migration.
    Al-Ghabkari A; Qasrawi DO; Alshehri M; Narendran A
    J Cancer Res Clin Oncol; 2019 Jun; 145(6):1461-1469. PubMed ID: 31006845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repurposing proscillaridin A in combination with decitabine against embryonal rhabdomyosarcoma RD cells.
    Huot M; Caron M; Richer C; Djibo R; Najmanovich R; St-Onge P; Sinnett D; Raynal NJM
    Cancer Chemother Pharmacol; 2021 Nov; 88(5):845-856. PubMed ID: 34331108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Artesunate induces ROS- and p38 MAPK-mediated apoptosis and counteracts tumor growth in vivo in embryonal rhabdomyosarcoma cells.
    Beccafico S; Morozzi G; Marchetti MC; Riccardi C; Sidoni A; Donato R; Sorci G
    Carcinogenesis; 2015 Sep; 36(9):1071-83. PubMed ID: 26153023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RAGE signaling deficiency in rhabdomyosarcoma cells causes upregulation of PAX7 and uncontrolled proliferation.
    Riuzzi F; Sorci G; Sagheddu R; Sidoni A; Alaggio R; Ninfo V; Donato R
    J Cell Sci; 2014 Apr; 127(Pt 8):1699-711. PubMed ID: 24554430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p21WAF1 expression induced by MEK/ERK pathway activation or inhibition correlates with growth arrest, myogenic differentiation and onco-phenotype reversal in rhabdomyosarcoma cells.
    Ciccarelli C; Marampon F; Scoglio A; Mauro A; Giacinti C; De Cesaris P; Zani BM
    Mol Cancer; 2005 Dec; 4():41. PubMed ID: 16351709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.